Skip to main content

Cancer

"In solid tumors, treat your RA patient as if they do not have a cancer, meaning do not change your therapy if the patient is responding well. Things may get dicey if hematologic malignancy." @RheumNow #RWCS24 I work w/ my onc team to ensure the patient has the needed support.

Dr. Rachel Tate @uptoTate( View Tweet )

Feb 15, 2024
Danish registries study shows maternal Autoimmune Dzs (all) were assoc w/ incr risk of childhood cancers (OR=1.25, 95% CI 1.06, 1.47), acute lymphoblastic leukemia (OR =1.52), Burkitt lymphoma (OR=2.6) & CNS tumors (OR=1.45); same seen for RA mothers https://t.co/HQO972ch9R https://t.co/dDEJUo8unq
Dr. John Cush @RheumNow( View Tweet )
Feb 10, 2024
Cancer and Myositis #RNL2024 @RheumNow @DrLisaCS on Cancer screening: Risk stratify: dermatomyositis, NXP2, TIFy, <40yo, refractory, dysphagia, cutaneous necrosis at higher risk Enhanced risk stratification for those at risks, versus "basic screening" for lower risks https://t.co/3yy9Fx1pk8
Eric Dein @ericdeinmd( View Tweet )
Jan 28, 2024
JAK toxicity of interest. Eric Ruderman #RNL2024 @RheumNow https://t.co/qdlJFKTUR8
Nouf Al hemmadi @NoufAhmedAlham2( View Tweet )
Jan 27, 2024
While NSAID use has been assoc w/ lower risk of cancers (CNS, breast, esophageal, gastric, head & neck, hepatocellular, cholangiocarcinoma, colorectal, endometrial, lung, ovary, prostate, pancreatic); NSAIDs should not be used to prevent cancers https://t.co/YcsU7x7iy0 https://t.co/QJjHqjnuEo
Dr. John Cush @RheumNow( View Tweet )
Jan 16, 2024

Increased CV Comorbidity in Dermatomyositis

Jan 11, 2024

A cohort study suggest that patients with dermatomyositis (DM) are at an increased risk for multiple comorbidities, including chronic kidney and cardiovascular disease,

Read Article
RA and cancer risk in the biologic era RA is known to be historically associated with site specific cancers, especially lung skin and lymphomas. This risk was described as likely to be supported by chronic systemic inflammation before the biologic era. https://t.co/ZOWFKTg3l3 https://t.co/1VLWgxVb0W
Dr. John Cush @RheumNow( View Tweet )
Dec 27, 2023

ICYMI: Cancer and TNF inhibitors

Cancer risk minimisation is a high priority for people with rheumatic diseases, as it is for the general population. Tumor necrosis factor inhibitors (TNFi) have a long history of association with cancer risk discussions. An oral presentation by Suarez-Almazor et al provided more supportive data

Read Article

FDA Warning on CAR-T Cell Therapy

Dec 07, 2023

On Nov. 28, 2024, FDA issued a safety alert regarding CAR-T cell immunotherapies; noting reports of T-cell malignancies (CAR-positive lymphoma) arising in patients treated with BCMA- or CD19-directed autologous CAR T cell immunotherapies and that if there is a risk, this only applies to 

Read Article

ICYMI: Are Rheumatologists doing Enough for Cervical Cancer?

Dec 07, 2023

Should rheumatologists be counseling patients on cervical cancer prevention and screening? The data from Abstract

Read Article
Are Rheumatologists doing Enough for Cervical Cancer? Should rheums be counseling patients on cervical cancer prevention and screening? The data from Abstract #1479 at #ACR23 suggests this should be an important conversation with our lupus patients. https://t.co/VFobM0T3u7 https://t.co/L45N3tsTdN
Dr. John Cush @RheumNow( View Tweet )
Nov 26, 2023

Are Rheumatologists doing Enough for Cervical Cancer?

Nov 15, 2023

Should rheumatologists be counseling patients on cervical cancer prevention and screening? The data from Abstract

Read Article
#ACR23 Abstr#2575 Do guidelines work? Data from UK cohort (N=290) re: utility of the International Guideline for IIM-assoc cancer screening detected 17 cases; most in high risk group & none in low risk. Need larger size, cases, screening timepoint & economic analysis @RheumNow https://t.co/G2bmmQbSox
Md Yuzaiful Md Yusof ( View Tweet )
Nov 15, 2023
Lung cancer in RA. @NamrataRheum et al. 26,625 RA HR for lung cancer for b/tsDMARDs vs csDMARDS 1.07 (0.91-1.26) Abstr#0453 #ACR23 @RheumNow https://t.co/NLNtyYoaoH https://t.co/tRpt62n62X
Richard Conway ( View Tweet )
Nov 14, 2023
Age does NOT affect the chance of getting irAE or the severity when using check point inhibitors to treat cancer. Data from #CANRIO database in #Canada #ACR 23 @ACRheum @RheumNow #1063 https://t.co/bqbiXzdAqr
Janet Pope ( View Tweet )
Nov 14, 2023
Obs study, bDMARDs & malignancy TNFi w/lower risk than ABA/RTX/IL6i & numerically lower than JAKs I'm a little skeptical... KM curves diverged w/~45 days, seems implausible? Agree w/first author, possible channeling bias @RheumNow #ACR23 Abstr 1678 https://t.co/1uL3j6kTSj
Mike Putman @EBRheum( View Tweet )
Nov 13, 2023

Cancer and TNF inhibitors

Cancer risk minimisation is a high priority for people with rheumatic diseases, as it is for the general population. Tumor necrosis factor inhibitors (TNFi) have a long history of association with cancer risk discussions. An oral presentation by Suarez-Almazor et al provided more supportive data

Read Article

#ACRbest Abstracts – Day 2

Nov 13, 2023

Our reporters have been prolific in finding the hot abstracts, those that were most attended or those that are getting the most buzz on social media.  Here are RheumNow's #ACRbest abstract reports from Monday, November 13, 2023 at #ACR23, covering The Great Debate, SGLPT2 inhibitors in SLE, the

Read Article
Large observational study of TNF use among patients with RA & cancer Overall encouraging, no negative impact on survival I'm kind of a TNF-truther on this; I don't think they cause ANY increased risk of malignancy @RheumNow #ACR23 Abstr 1675 https://t.co/KRVlIFxhl8
Mike Putman @EBRheum( View Tweet )
Nov 13, 2023
2 RA cohorts w/Breast Cancer 17% TNFi within 1yr after surgery No diff in overall survival at 5 yr w/ TNFi or csDMARD Trend towards better BC specific survival w/ TNFi vs. csDMARD only Worst survival for GC>7.5mg/day Only 2 yrs follow up @RheumNow #ACR23 ABST1675 https://t.co/ekKlJ2dP5i
Aurelie Najm ( View Tweet )
Nov 13, 2023
1-Can we prevent RA ? Vagotomy? 2-CV events in auto immune rheumatic disease pregnancies. 3-CVS vasculitis , challenges and role of Brain biopsy And others…….. https://t.co/BX8bDSX1M3 @RheumNow , daily recap #ACR23

Nouf Al hemmadi ( View Tweet )

Nov 13, 2023
No more underpowered long-term safety studies We need a "SELECT-SURVEILLANCE" study to replicate ORAL-SURVEILLANCE & tell us if UPA has the same MACE/cancer risk as TOFA Minus that, I plan to go 100% TOFA when it becomes generic in 2026 @RheumNow #ACR23 Abstr1326 https://t.co/LyQ1Q8qReO
Mike Putman @EBRheum( View Tweet )
Nov 13, 2023
Yet another (mostly) reassuring report about lymphoma and DMARDS The skin cancer signal in the CIRT trial was weird; would be worth looking into that in observational studies as well @NamrataRheum #ACR23 Abst0438 @RheumNow https://t.co/Beg8UUe2mn
Mike Putman @EBRheum( View Tweet )
Nov 12, 2023
Nice VA study evaluating risk of lung cancer w/respect to RA treatment strategies Take home? No association. Aside from the (small risk) w/JAKi's, I think malignancy risks have been mostly overblown @NamrataRheum @RheumNow ABST0453 #ACR23 https://t.co/lDz0nV1KHt
Mike Putman @EBRheum( View Tweet )
Nov 12, 2023

ACR Convergence Preview (11.10.2023)

Nov 10, 2023

Dr. Jack Cush reviews this past week's news on RheumNow.com and suggests a learning plan for those wanting to consume the upcoming ACR Convergence 2023 meeting. 




  1. 2023 Medscaped Female Compensation Survey asked What percentage would again chose their specialty ? Top 5

Read Article